


In re: Leutenegger, et al  
Inter'l Appl. No.:PCT/DE00/02262  
Page 4 of 7

REMARKS

The above amendments are made to more clearly define the invention under United States practice. Please enter this amendment prior to calculation of the filing fee.

Respectfully submitted,




Raymond O. Linker, Jr.  
Registration No. 26,419

**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Charlotte Office (704) 444-1000  
Fax Charlotte Office (704) 444-1111  
**Customer No. 00826**

**CERTIFICATE OF EXPRESS MAILING**

"Express Mail" mailing label number EL 822757774 US  
Date of Deposit January 8, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner For Patents, Washington, DC 20231.

  
Lorna Morehead

**Version With Markings to Show Changes Made:**

1. (Amended) Vaccine for the protective vaccination or therapy of a lentivirus infection in *Felidae* [which has the characteristic that it contains] comprising an immunising polynucleotide sequence which contains or consists of at least a part of the gene of a protein of the corresponding virus, particularly of the envelope protein (*env* gene), under the control of a eukaryotic promoter which is active in the corresponding animal.
2. (Amended) Vaccine in accordance with Claim 1 [which has the characteristic that] wherein the lentivirus is a lentivirus of an animal of the genus *Felidae*, specifically the domestic cat.
3. (Amended) Vaccine in accordance with Claim 2 [which has the characteristic that] wherein the lentivirus is the feline immune deficiency virus (FIV).
4. (Amended) Vaccine in accordance with [Claims 1 to 3 which has the characteristic that] Claim 1 wherein the immunising polynucleotide sequence contains a coding sequence which contains or consists of the extraviral or extracellularly situated domain of the *env* gene product, or a part of this.
5. (Amended) Vaccine in accordance with Claim 4 [which has the characteristic that] wherein the immunising polynucleotide sequence contains or consists of a coding sequence for at least twenty aminoacids of the transmembrane portion of the *env* gene product.
6. (Amended) Vaccine in accordance with [Claims 1 to 5 which has the characteristic that it] Claim 1 which also contains at least one immunising section of the gene coding for an internal protein of the lentivirus[, for example the *gag* gene].
7. (Amended) Vaccine in accordance with [claims 1 to 6 which has the characteristic that] Claim 1 wherein the immunising polynucleotide sequence contains the coding sequence (SEQ ID NO. 4) of the plasmid sequence given under SEQ ID NO 1 or a sequence

which is 85% identical with the coding sequence (SEQ ID NO 4) of the plasmid sequence given under SEQ ID NO 1, or a coding sequence which, without degeneration of the genetic code, is at least 85% identical with the coding sequence of the sequence given under SEQ ID NO 1.

8. (Amended) Vaccine in accordance with [Claims 1 to 7 which is characterised by] Claim 1 containing an accessory polynucleotide sequence which contains the sequences coding for IL-12 under the control of one or more eukaryotic promoters which are active in the corresponding animal.

9. (Amended) Vaccine in accordance with [Claims 1 to 7 which is characterised by] Claim 1 containing an accessory polynucleotide sequence which contains the sequence coding for IL-16 under the control of a eukaryotic promoter which is active in the corresponding animal.

10. (Amended) Vaccine in accordance with [Claims 1 to 7 which is characterised by] Claim 1 containing an accessory polynucleotide sequence which contains the sequence coding for IL-12 and IL-16 under the control of one or more eukaryotic promoters which are active in the corresponding animal.

11. (Amended) Vaccine in accordance with [Claims 8 to 10 which is characterised by] Claim 8 containing an accessory polynucleotide sequence which codes for both subunits of feline IL-12 and/or for feline IL-16 and [that] wherein these sequences are under the control of a eukaryotic promoter which is active in the cat.

12. (Amended) Vaccine in accordance with [Claims 8 to 11 which is characterised by] Claim 8 containing an accessory polynucleotide sequence which contains at least one base sequence of the type  $N^1N^2CGN^3N^4$ , where  $N^1N^2$  is an element of the group GT, GG, GA, AT or AA and  $N^3N^4$  is an element of the group CT or TT.

13. (Amended) Vaccine in accordance with [at least one of Claims 1 to 12 which is characterised by the fact that] Claim 1 in which the immunising polynucleotide sequences and/or

the accessory polynucleotide sequences are present as expression constructs which consist of linear and covalently capped molecules of desoxyribonucleic acid which contain a linear double-stranded region and in which the single strands which combine to form double strands are connected by short single-stranded loops of desoxyribonucleic acid and in which the single strands which combine to form double strands only consist of the coding sequence, a terminator sequence and a promoter which is active in the animal which is immunised.

14. (Amended) Vaccine in accordance with [Claims 8 to 13 which is characterised by the fact that] Claim 8 in which the accessory polynucleotide sequence contains a coding sequence in accordance with SEQ ID NO 8 (IL-12 p40), a coding sequence in accordance with SEQ ID NO 9 (IL-12 p35), coding sequences SEQ ID NO 10 (IL-16), SEQ ID NO 5 (CpG) or SEQ ID NO 6 (CpG) or a sequence which is complementary to one of these sequences.

15. (Amended) Vaccine [in accordance with Claims 1 to 14] for the vaccination or therapy of lentivirus infections in animals characterised by the presence of an immunising polynucleotide sequence and, in some cases, an accessory polynucleotide sequence in accordance with [Claims 8 to 12] Claim 8, applied to a suitable massive and inert carrier material, in such a way that it can be accelerated into the skin of the animal, penetrate into the cells of the animal and be expressed there.

17. (Amended) Vaccine in accordance with [Claims 15 or 16] Claim 15 which is characterised by the carrier material being gold.

18. (Amended) Vaccine for the protective vaccination or therapy of an infection with lentivirus in *Felidae* which is characterised by the fact that it contains an immunising protein or [part of a protein, particularly] the envelope protein of the corresponding lentivirus, together with IL-12 and/or IL-16 in the form of protein.